DUB

信号通路图

研究领域

抑制剂选择性比较

特异性亚型抑制剂

DUB产品

所有产品 DUB抑制剂(10)

产品目录	产品描述	文献引用	实验数据
S2243	Degrasyn (WP1130) Degrasyn (WP1130)是一种选择性deubiquitinase (DUB: USP5，UCH-L1，USP9x，USP14，和 UCH37)抑制剂，对Bcr/Abl也有抑制作用，也是一种JAK2传感器(不影响20S蛋白酶体)和转录激活剂(STAT)。	Cancer Lett, 2018, 436:129-138 Cells, 2018, 10.3390/cells7080091 Am J Transl Res, 2018, 10(1):224-234	Protein expression by western blot analysis of cell lysates from MCF-7, TAM^R-4 and 164^R-7 cells treated for 3 days with vehicle (0.1% DMSO), 1 uM or 1.5 uM WP1130.
S7130	PR-619 PR-619是一种非选择性的，deubiquitinylating enzymes (DUBs)可逆抑制剂，无细胞试验中EC50为1-20 μM。	Cell Rep, 2019, 27(6):1657-1665 Cell Rep, 2019, 26(11):3076-3086.e6 Mol Cell, 2018, 70(2):211-227	Ubiquitination inhibitor PYR-41 and deubiquitination inhibitor PR-619 pretreated macrophages with or without Teuvincenone F (25 μM) for 2 h, following stimulated with LPS (100 ng/ml) for 30 min, and then subjected to immunoprecipitation with anti-NEMO antibody followed by immunoblot analysis with specific antibodies. Similar results were obtained from three independent experiments.
S7132	P5091 (P005091) P5091 (P005091)是一种选择性的，有效的ubiquitin-specific protease 7 (USP7)（泛素特异性蛋白酶7）抑制剂，EC50为4.2 μM，与作用于USP47相似。	Haematologica, 2019, 10.3324/haematol.2018.206227 J Exp Clin Cancer Res, 2019, 38(1):90 Biochem Biophys Res Commun, 2019, 512(3):479-485	(e) MM.1S cells were treated with RRx-001 (1.25 μM), P5091 (3 μM) or RRx-001 plus P5091 for 12 h; protein extracts were analyzed for total DNMT activity using the EpiQuik DNMT activity kit (mean±s.d.; P<0.001; n=3). (f) MM.1S cells were treated with RRx-001 (1.25 μM), P5091 (3 μM) or RRx-001 plus P5091 for 12 h; protein lysates were then subjected to immunoblot analysis using antibodies specific against p21, HDM2, p53 or GAPDH.
S7134	IU1 IU1是一种细胞渗透性的，可逆的proteasome（蛋白酶体）选择性抑制剂，作用于USP14时，IC50为4.7 μ M，作用于IsoT时选择性高25倍。	J Exp Clin Cancer Res, 2019, 38(1):220 Glia, 2018, 66(2):379-395 Eur J Immunol, 2018, 10.1002/eji.201847603	IU1 treatment increased levels of peIF2a in both WT and S63del L. Sciatic nerves were treated ex vivo with 200 lM IU1 for 16 hr and the levels of p-eIF2a and eIF2a were analyzed by western blot. A Student’s t-test was performed between treated and untreated conditions of the same genotype
S7135	LDN-57444 LDN-57444是一种可逆的竞争性的蛋白酶体抑制剂，抑制Uch-L1时，IC50为0.88 μM，比作用于亚型Uch-L3选择性高30倍。	J Cell Mol Med, 2017, 21(12):3641-3657	Representative results of Western blot showed the effects of LDN (10.0 μM) treatments on the expressions of LC3-II and LC3-I from Normoxia and OGD groups of cPKCc+/+ and cPKCc/ cortical neurons (n = 6 per group).
S7140	TCID TCID是一种DUB抑制剂，抑制ubiquitin C-terminal hydrolase L3（泛素C-末端水解酶L3），IC50为0.6 μM，作用于L1选择性高125倍。
S7133	P22077 P22077是一种ubiquitin-specific protease USP7（泛素特异性蛋白酶USP7）抑制剂，EC50为8.6 μM，也抑制USP47。	Biochem Biophys Res Commun, 2019, 512(3):479-485
S4920	b-AP15 b-AP15是一种deubiquitinases（去泛素化酶）抑制剂，识别19S蛋白酶体的，抑制Ub-AMC分解， IC50为2.1 μM。	Mol Cancer Ther, 2019, 18(6):1045-1056 Int J Biochem Cell Biol, 2016, 79:350-359	A USP14 inhibitor directly inhibits OSCC cell proliferation and triggers apoptosis. (A-D) OSCC cells were treated with indicated doses of b-AP15 for 24 h. (A) Cell proliferation was monitored by CCK8 assay. b-AP15 dramatically decreased cancer cells viability in a dose-dependent manner (p < 0.01). All values represented means ± SD of three independent experiments and each was performed in triplicate. (B, C) Flow cytometry analysis indicated that b-AP15 triggered significant apoptosis of OSCC cells (p < 0.01). Data were obtained in more than three independent experiments. (D) Apoptosis-related proteins were examined by western blot analysis. Inhibition of USP14 with b-AP15 induced a massive increase of ubiquitinated proteins, which then triggered apoptosis of cancer cells, activating caspase 3 to induce cleavage of caspase 3 and PARP.
S8288	VLX1570 VLX1570是蛋白酶DUB的竞争性抑制剂，在体外IC50值约为10μM。
S7529	ML323 ML323 是强效的选择性的USP1-UAF1抑制剂，其IC50为76 nM。	Oncol Rep, 2017, 37(3):1419-1429

产品目录	产品描述	文献引用	实验数据
S2243	Degrasyn (WP1130) Degrasyn (WP1130)是一种选择性deubiquitinase (DUB: USP5，UCH-L1，USP9x，USP14，和 UCH37)抑制剂，对Bcr/Abl也有抑制作用，也是一种JAK2传感器(不影响20S蛋白酶体)和转录激活剂(STAT)。	Cancer Lett,2018, 436:129-138 Cells,2018, 10.3390/cells7080091 Am J Transl Res,2018, 10(1):224-234	Protein expression by western blot analysis of cell lysates from MCF-7, TAM^R-4 and 164^R-7 cells treated for 3 days with vehicle (0.1% DMSO), 1 uM or 1.5 uM WP1130.
S7130	PR-619 PR-619是一种非选择性的，deubiquitinylating enzymes (DUBs)可逆抑制剂，无细胞试验中EC50为1-20 μM。	Cell Rep,2019, 27(6):1657-1665 Cell Rep,2019, 26(11):3076-3086.e6 Mol Cell,2018, 70(2):211-227	Ubiquitination inhibitor PYR-41 and deubiquitination inhibitor PR-619 pretreated macrophages with or without Teuvincenone F (25 μM) for 2 h, following stimulated with LPS (100 ng/ml) for 30 min, and then subjected to immunoprecipitation with anti-NEMO antibody followed by immunoblot analysis with specific antibodies. Similar results were obtained from three independent experiments.
S7132	P5091 (P005091) P5091 (P005091)是一种选择性的，有效的ubiquitin-specific protease 7 (USP7)（泛素特异性蛋白酶7）抑制剂，EC50为4.2 μM，与作用于USP47相似。	Haematologica,2019, 10.3324/haematol.2018.206227 J Exp Clin Cancer Res,2019, 38(1):90 Biochem Biophys Res Commun,2019, 512(3):479-485	(e) MM.1S cells were treated with RRx-001 (1.25 μM), P5091 (3 μM) or RRx-001 plus P5091 for 12 h; protein extracts were analyzed for total DNMT activity using the EpiQuik DNMT activity kit (mean±s.d.; P<0.001; n=3). (f) MM.1S cells were treated with RRx-001 (1.25 μM), P5091 (3 μM) or RRx-001 plus P5091 for 12 h; protein lysates were then subjected to immunoblot analysis using antibodies specific against p21, HDM2, p53 or GAPDH.
S7134	IU1 IU1是一种细胞渗透性的，可逆的proteasome（蛋白酶体）选择性抑制剂，作用于USP14时，IC50为4.7 μ M，作用于IsoT时选择性高25倍。	J Exp Clin Cancer Res,2019, 38(1):220 Glia,2018, 66(2):379-395 Eur J Immunol,2018, 10.1002/eji.201847603	IU1 treatment increased levels of peIF2a in both WT and S63del L. Sciatic nerves were treated ex vivo with 200 lM IU1 for 16 hr and the levels of p-eIF2a and eIF2a were analyzed by western blot. A Student’s t-test was performed between treated and untreated conditions of the same genotype
S7135	LDN-57444 LDN-57444是一种可逆的竞争性的蛋白酶体抑制剂，抑制Uch-L1时，IC50为0.88 μM，比作用于亚型Uch-L3选择性高30倍。	J Cell Mol Med,2017, 21(12):3641-3657	Representative results of Western blot showed the effects of LDN (10.0 μM) treatments on the expressions of LC3-II and LC3-I from Normoxia and OGD groups of cPKCc+/+ and cPKCc/ cortical neurons (n = 6 per group).
S7140	TCID TCID是一种DUB抑制剂，抑制ubiquitin C-terminal hydrolase L3（泛素C-末端水解酶L3），IC50为0.6 μM，作用于L1选择性高125倍。
S7133	P22077 P22077是一种ubiquitin-specific protease USP7（泛素特异性蛋白酶USP7）抑制剂，EC50为8.6 μM，也抑制USP47。	Biochem Biophys Res Commun,2019, 512(3):479-485
S4920	b-AP15 b-AP15是一种deubiquitinases（去泛素化酶）抑制剂，识别19S蛋白酶体的，抑制Ub-AMC分解， IC50为2.1 μM。	Mol Cancer Ther,2019, 18(6):1045-1056 Int J Biochem Cell Biol,2016, 79:350-359	A USP14 inhibitor directly inhibits OSCC cell proliferation and triggers apoptosis. (A-D) OSCC cells were treated with indicated doses of b-AP15 for 24 h. (A) Cell proliferation was monitored by CCK8 assay. b-AP15 dramatically decreased cancer cells viability in a dose-dependent manner (p < 0.01). All values represented means ± SD of three independent experiments and each was performed in triplicate. (B, C) Flow cytometry analysis indicated that b-AP15 triggered significant apoptosis of OSCC cells (p < 0.01). Data were obtained in more than three independent experiments. (D) Apoptosis-related proteins were examined by western blot analysis. Inhibition of USP14 with b-AP15 induced a massive increase of ubiquitinated proteins, which then triggered apoptosis of cancer cells, activating caspase 3 to induce cleavage of caspase 3 and PARP.
S8288	VLX1570 VLX1570是蛋白酶DUB的竞争性抑制剂，在体外IC50值约为10μM。
S7529	ML323 ML323 是强效的选择性的USP1-UAF1抑制剂，其IC50为76 nM。	Oncol Rep,2017, 37(3):1419-1429